Study focuses on slowing the effects of Alzheimer’s
An experimental treatment appears to delay Alzheimer's symptoms in some people genetically destined to get the disease in ...
INQUIRER.net USA1d
Researchers find a hint at how to delay Alzheimer’s symptoms
An experimental treatment appears to delay Alzheimer’s symptoms in some people genetically destined to get the disease in ...
Alzheimer’s-related dementia could be prevented by experimental drug, researchers say
For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of ...
Science Daily2d
Gene Therapy News
Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...
Precision Medicine Online2d
Alnylam's RNAi TTR Silencing Drug Amvuttra FDA Approved for Transthyretin Amyloidosis Cardiomyopathy
The drug was already sold for TTR amyloidosis with polyneuropathy, and now is available to patients with hereditary or wild-type ATTR-CM.
New Atlas2d
Alzheimer’s prevention hope as drug cuts deadly disease onset in half
A long-term human trial has found that a discontinued drug halved the presentation of early-onset Alzheimer's disease in ...
MedPage Today on MSN2d
Vutrisiran Snags FDA Approval for TTR Amyloidosis Cardiomyopathy
Gene-silencing therapy vutrisiran (Amvuttra) graduated to a broad indication in treatment of transthyretin amyloidosis ...
BioSpace3d
Alnylam’s Amvuttra Approved as First RNAi Silencer for Rare Type of Cardiomyopathy
The FDA approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin ...